Parkinson's disease is a very common neurodegenerative disorder with no proven neuroprotective or neurorestorative therapies. Recent advances in identifying genetic causes of Parkinson's disease have provided new opportunities for discovery of therapeutic targets and agents to potentially prevent the degenerative process of Parkinson's disease. Individuals with LRRK2 mutations are clinically and neurochemically indistinguishable from those with idiopathic Parkinson's disease 1 . Disease-segregating mutations in LRRK2 lead to neurotoxicity in vitro [2] [3] [4] and loss of dopamine neurons in people with Parkinson's disease 5 . LRRK2 toxicity in vitro is linked to kinase activity and GTP binding, as mutations in LRRK2 that interfere with kinase activity and GTP binding inhibit toxicity. Whether LRRK2 toxicity requires kinase activity in vivo and whether pharmacologic inhibition of this activity would protect against LRRK2 toxicity is not known.
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To identify LRRK2 inhibitors, we monitored LRRK2 autophosphorylation ( Fig. 1) and LRRK2-mediated phosphorylation of myelin basic protein (MBP) (Supplementary Fig. 1 ) in the presence or absence of 84 kinase and phosphatase inhibitors at 16 μM (all from Biomol; see Supplementary Methods and Supplementary Table 1) . Indolinone compounds including staurosporine (compound 6), GF 109203X (compound 31), Ro 31-8220 (compound 33), 5-iodotubercidin (compound 49), GW5074 (compound 56) and indirubin-3′-monooxime (compound 70) and anthracene compounds SP 600125 (compound 68) and damnacanthal (compound 22) substantially inhibited LRRK2 autophosphorylation (Fig. 1a,b) and LRRK2-mediated phosphorylation of MBP (Supplementary Fig. 1a,b) . None of the inhibitors substantially enhanced LRRK2 kinase activity.
The half-maximal inhibitory concentrations of these eight inhibitors were determined against autophosphorylation and MBP phosphorylation by wild type (WT) and G2019S LRRK2 (Fig. 1c,d,  Supplementary Fig. 1c,d and Supplementary Table 2 ). All of the inhibitors except indirubin-3′-monooxime had relatively similar potencies against WT and G2019S LRRK2 autophosphorylation activity (Fig. 1c,d and Supplementary Table 2 ). Indirubin-3′-monooxime more potently inhibited G2019S LRRK2 autophosphorylation (Fig. 1c,d and Supplementary Table 2) . Staurosporine, damnacanthal, SP 600125, and 5-iodotubercidin equivalently inhibited both WT and G2019S LRRK2 MBP phosphorylation ( Supplementary  Fig. 1c,d and Supplementary Table 2 ). Both protein kinase C inhibitors, Ro 31-8220 and GF109203X, more potently inhibited both WT and G2019S LRRK2 MBP phosphorylation, and GW5074 was less potent in inhibiting both WT and G2019S LRRK2 MBP phosphorylation than WT and G2019S LRRK2 autophosphorylation (Fig. 1c,d,  Supplementary Fig. 1c,d and Supplementary Table 2 ). All eight inhibitors had a similar inhibitory profile against LRRK1 autophosphorylation and MBP phosphorylation ( Supplementary Fig. 2a-d) .
Given that LRRK2 and LRRK1 are related to the MAP kinase kinase kinase Raf 6 and GW5074 inhibits Raf kinase 7 , we monitored LRRK2 and LRRK1 autophosphorylation and MBP phosphorylation in the presence or absence of additional Raf kinase inhibitors ZM336372, sorafenib and Raf inhibitor IV (Fig. 1e) . GW5074 more potently inhibited G2019S LRRK2 autophosphorylation and MBP phosphorylation than it did WT LRRK1 autophosphorylation and MBP phosphorylation (Fig. 1f,g,  Supplementary Figs . 1e,f and 2e and Supplementary Table 3) . ZM336372 had minimal to no effect on LRRK1 autophophorylation and MBP phosphorylation and no effect on WT or G2019S LRRK2 autophosphorylation and MBP phosphorylation (Fig. 1e-g, Supplementary  Figs . 1e,f and 2e and Supplementary Table 3 ). Both sorafenib and Raf inhibitor IV inhibited LRRK2 autophosphorylation and MBP phosphorylation with less potency than GW5074, but they had minimal to no effect on LRRK1 autophosphorylation or MBP phosphorylation (Fig. 1e-g, Supplementary Figs . 1e,f and 2e and Supplementary Table 3 ). These results indicate that GW5074 inhibits both LRRK2 and LRRK1 kinase activities, whereas sorafenib and Raf inhibitor IV are relatively selective for LRRK2 kinase activity and ZM336372 has minimal to no effect on LRRK2 and LRRK1 kinase activities. We also compared indirubin-3′-monooxime and the related analog indirubin against WT LRRK1, WT LRRK2 and G2019S LRRK2 autophosphorylation and MBP phosphorylation. Indirubin-3′-monooxime inhibited WT LRRK1, WT LRRK2 and G2019S LRRK2 autophosphorylation and MBP phosphorylation, whereas indirubin had no effect on WT LRRK1, WT LRRK2 and G2019S LRRK2 autophosphorylation or MBP phosphorylation (Supplementary Table 3 ). GW5074 and indirubin-3′-monooxime also inhibited LRRK2-mediated phosphorylation of eukaryotic translation initiation factor 4E-binding protein (4E-BP1), a putative physiologic LRRK2 substrate 8 , whereas ZM336372 and indirubin did not inhibit LRRK2 phosphorylation of 4E-BP1 (Fig. 1h,i) .
Both WT LRRK2 and G2019S LRRK2 overexpression led to primary cortical neuron injury, as assessed by neurite shortening (Fig. 2a,b and Supplementary Fig. 3 ), and G2019S LRRK2 overexpression led to cell death, as assessed by DNA fragmentation (TUNEL assay) (Fig. 2c,d and Supplementary Methods), whereas kinase-dead (D1994A) versions of LRRK2 and G2019S LRRK2 were devoid of toxicity, as previously described 3,4,9 ( Fig. 2a-d and Supplementary  Fig. 3) . Treatment of the cortical cultures with 0.5 μM GW5074 and 0.5 μM indirubin-3′-monooxime, which inhibit both LRRK2 and LRRK1, attenuated G2019S LRRK2 cell injury and cell death (Fig. 2b,d) . The Raf kinase inhibitor sorafenib (0.5 μM), which is relatively selective for LRRK2 (see Supplementary Table 3) , also completely protected against G2019S LRRK2 toxicity (Fig. 2b,d and Supplementary Fig. 3 ). The Raf kinase inhibitor ZM336372 (0.5 μM), which does not inhibit LRRK2 or LRRK1 kinase activity, failed to inhibit G2019S LRRK2 toxicity (Fig. 2b,d and Supplementary Fig. 3 ). The cyclin-dependent kinase and glycogen synthase kinase-3β (GSK-3β) inhibitor indirubin, which does not inhibit LRRK2 or LRRK1 kinase activity, failed to inhibit G2019S LRRK2 toxicity (Fig. 2b,d and Supplementary Fig. 3) . These results taken together indicate that the protection afforded by the Raf inhibitors (GW5074 and sorafenib) and the cyclindependent kinase and GSK-3β inhibitor (indirubin-3′-monooxime) are due to inhibition of LRRK2 kinase activity and not inhibition of Raf, cyclin-dependent or GSK-3β kinase activity.
To determine the efficacy of the LRRK2 kinase inhibitors in vivo, we developed a herpes simplex virus (HSV) amplicon-based mouse model of LRRK2 dopaminergic neurotoxicity (Fig. 2e-h and Supplementary Methods). GFP was extensively co-expressed with tyrosine hydroxylase and in ~75% of substantia nigra compacta neurons after an intrastriatal HSV-eGFP injection ( Supplementary  Fig. 4 ). Immunoblot analysis confirmed that WT, G2019S and G2019S-D1994A LRRK2 are overexpressed in equivalent amounts (Fig. 2e) . HSV amplicon-mediated delivery of LRRK2 G2019S induced significant loss of tyrosine hydroxylase-positive neurons 3 weeks after stereotaxic injection into the ipsilateral striatum of mice compared to control viruses expressing WT LRRK2 and eGFP (Fig. 2f,g ). HSV amplicon-mediated delivery of G2019S-D1994A LRRK2 caused no neuronal loss, similarly to WT LRRK2 and GFP control viruses (Fig. 2f,g ). Because GW5074 and indirubin-3′-monooxime and indirubin are known to cross the blood-brain barrier 7,10,11 , we chose them to test whether inhibition of LRRK2 kinase activity is protective in vivo. Twice daily injections of the LRRK2 kinase inhibitors, GW5074 and indirubin-3′-monooxime, (2.5 mg per kg body weight intraperitoneally) attenuated the loss of tyrosine hydroxylase-positive neurons induced by HSV-G2019S LRRK2 compared to DMSO-and indirubin-injected controls (Fig. 2f,h) . The density of tyrosine hydroxylase-positive fibers was also reduced in mice given HSV-LRRK2 G2019S compared to those given HSV-eGFP control and HSV-WT LRRK2, and the reduction in the density of tyrosine hydroxylase-positive fibers was rescued by GW5074 (Supplementary Fig. 5 ). Mice transduced with eGFP and WT LRRK2 did not show any signs of inflammation as determined by isolectin B 4 (ILB4) staining, but G2019S LRRK2 induced a significant increase in ILB 4 -positive cells in the striatum and substantia nigra pars compacta, which was also prevented by administration of GW5074 (Supplementary Fig. 6 ). The major finding of this paper is the identification of kinase inhibitors that inhibit LRRK2 kinase activity and protect against LRRK2 toxicity both in vitro and in vivo. Other kinase inhibitors have recently been reported to inhibit LRRK2 kinase activity with similar potencies to those described here [12] [13] [14] [15] . Given that an authentic substrate of LRRK2 has yet to be identified, there should be a note of caution regarding the physiological relevance of the screens used in this and related studies based on autophosphorylation and artificial substrates. These results hold particular promise for further studies focused on developing selective and potent inhibitors of LRRK2 kinase activity. Moreover, they demonstrate that pharmacologic inhibition of LRRK2 kinase activity is a potentially promising therapeutic modality for the treatment of neurodegeneration in Parkinson's disease. *** ***
